News & Updates

A study conducted at the Cancer Genetics Clinic of the National University Cancer Institute, Singapore underlines the use of germline genetic testing in guiding therapeutic decisions in individuals with advanced cancers.

In patients with HRD+ advanced epithelial OC harbouring BRCA wild-type tumours, integrating durvalumab induction and durvalumab plus olaparib maintenance into 1L bevacizumab-containing chemotherapy significantly extends PFS and PFS2, suggest updated results from the DUO-O trial.

Adding olanzapine to prophylactic antiemetic medications appeared to substantially improve nausea and vomiting control among patients receiving moderately emetogenic chemotherapy (MEC) regimens in a phase III randomized clinical trial.

Liver transplantation (LT) in combination with chemotherapy, as opposed to chemotherapy alone, can provide a meaningful improvement in survival among patients with unresectable colorectal liver metastases, suggest the results of the TRANSMET trial presented at ESMO GI 2024.

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) appear to fare better with tenofovir than with entecavir, with a recent study showing that prognosis is better for those who have been treated with tenofovir.

The investigational garsorasib, a potent KRASG12C inhibitor, appears to induce high response rate while having a manageable safety profile in patients with previously treated KRASG12C-mutated non–small cell lung cancer (NSCLC), according to the results of a phase II study.